Trial Profile

A Multicenter, Prospective Observational RWE Study to Assess Patient-reported Wellbeing Using Tildrakizumab in a Live Setting - POSITIVE Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tildrakizumab (Primary)
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms POSITIVE
Sponsors Almirall S.A.

Most Recent Events

11 May 2025 Status changed from active, no longer recruiting to completed.
26 Sep 2024 According to Sun Pharmaceutical Industries Media Release, company announced that data from this study will be presented as 12 poster presentations at at the 33rd European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlands from September 25-28, 2024.
30 Jul 2024 Planned End Date changed from 1 Dec 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com